- 中文名稱
Anti-Human HB-EGF
- 英文名字
- Anti-Human HB-EGF
- 供應商
- ReliaTech
- 產品貨號
- 101-M447
- 產品報價
- ￥詢價/100ug
- 產品說明書
- 點擊查看
- 購買方式
- 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868
- 產品新聞
- 背景資料
- HB-EGF was originally purified based on its heparin-binding property and mitogenic activity on BALB/3T3 fibroblasts from the conditioned medium of the human U937 histiocytic lymphoma cell line. The natural protein has an apparent molecular mass of 19-23 kDa and exists in multiple forms as a result of heterogenous O-glycosylation and/or N-terminal truncation. In addition to fibroblasts, HB-EGF is also a potent mitogen for keratinocytes and smooth muscle cells but not for capillary endothelial cells. HB-EGF is produced in monocytes and macrophages. In addition, transcription of HB-EGF can be induced in vascular endothelial cells as well as aortic smooth muscle cells (SMC), suggesting that HB-EGF may have an important role in the pathogenesis of atherosclerosis. HB-EGF is a member of the EGF family of mitogens which also include transforming growth factorα (TGFα), amphiregulin (AR), rat schwanoma-derived growth factor (SDGF), vaccinia growth factor (VGF), and the various ligands for the HER2/ErbB2/Neu receptor. All these cytokines are derived from transmembrane precursors that contain one or several EGF structural units in their extracellular domain. Many of these transmembrane precursors are biologically active and seem to play a role in juxtacrine stimulation of adjacent cells. The cDNA for HB-EGF encodes a 204 amino acid residue transmembrane protein that is proteolytically cleaved to generate the soluble HB-EGF. Like EGF, TGFα, and AR? HB-EGF binds to the EGF receptor and activates the receptor tyrosine kinase. HB-EGF is reported to be a more potent SMC mitogen than EGF. It has been suggested that the differential activities found for HB-EGF compared to EGF may be mediated by the heparin-binding properties of HB-EGF. A diphtheria toxin receptor that mediates the endocytosis of the bound toxin has been cloned and found to be identical to the transmembrane HB-EGF precursor.
- 應用類型
- WB, N
- 免疫原
- 該Anti-Human HB-EGF的詳細信息查看ReliaTech提供的產品說明書。
- 來源宿主
- 該Anti-Human HB-EGF的詳細信息查看ReliaTech提供的產品說明書。
- 反應性
- 該Anti-Human HB-EGF的詳細信息查看ReliaTech提供的產品說明書。
- 保存建議
- 該Anti-Human HB-EGF的詳細信息查看ReliaTech提供的產品說明書。溶解建議：Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.
- 其他
- ReliaTech全稱為受體配體技術有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國不倫瑞克，是一家后基因組生物技術公司。ReliaTech主要專注于受體和配體的發現與研究。此外，ReliaTech也開發應用于血管與淋巴管生成研究的相關高品質試劑。目前ReliaTech提供近2800款產品，產品線主要包括重組蛋白(細胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。
- 注意
-
該頁面的中文產品信息的翻譯，僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前，請瀏覽說明書確認。
-
